Olek Honored at Exclusive Three-Day Event Where International Leaders Connect
                     With 100 Top Innovators Under Age 35

    BERLIN and CAMBRIDGE, Mass., May 23 /PRNewswire/ -- Epigenomics AG, a
transatlantic biotech company pioneering the applications of DNA methylation,
today announced that its CEO, Dr. Alex Olek, has been chosen as one of the
world's 100 Top Young Innovators by Technology Review, MIT's Magazine of
Innovation.  The TR100, chosen by Technology Review, MIT's award-winning
magazine of innovation, consists of 100 young individuals whose innovative
work in business and technology has a profound impact on today's world.
Nominees are recognized for their contribution in transforming the nature of
technology in industries such as biotechnology, computing, energy, medicine,
manufacturing, nanotechnology, telecommunications and transportation.
    Epigenomics, which Olek co-founded in 1998 in Berlin, has grown from a
five-member founding team in a Berlin backyard to a transatlantic Biotech
concern with a total of over 100 staff in Berlin and Seattle. Epigenomics uses
a certain digital DNA methylation patterns to enable the early detection and
improved classification of complex diseases, such as cancer. Epigenomics is
spearheading molecular diagnostics and associated applications essential for
the development of tomorrow's personalized medicine.
    "It's a great honor being included for such a prestigious award," noted
Olek. "In only a short space of time, Epigenomics has achieved many exciting
milestones. However, I must share this honor with my teams in Berlin and
Seattle, whose dedication and loyalty must also be recognized."
    Olek is being honored today during a conference and awards ceremony at the
Massachusetts Institute of Technology. The event, themed "The Innovation
Economy: How Technology is Transforming Existing Businesses and Creating New
Ones", includes a full day of conference sessions and panel discussions
followed by an evening gala awards ceremony. Hosted by Technology Review's
Editor-in-Chief John Benditt and CNBC's Consuelo Mack, conference speakers
include international leaders such as Kenneth Starr Esq.; Clayton Christensen,
Harvard Business School professor and author of The Innovators Dilemma; Nadine
Strossen, president of the ACLU; Rodney Brooks, Director of the Artificial
Intelligence Laboratory and Co-director of Project Oxygen, MIT; Richard
Rashid, Senior Vice President, Microsoft Research; and David Tennenhouse, Vice
President and Corporate Technology Group Director, Intel Corporation.

     TR100's panel of judges includes:

     *  Dr. David Baltimore, President, California Institute of Technology
     *  Alfred Berkeley III, Vice Chairman, Nasdaq
     *  Richard Demillo, Vice President and Chief Technology Officer,
        Hewlett-Packard
     *  Dr. Philippe Janson, Vice President, IBM Academy of Technology
     *  Dr. Robert M. Metcalfe, Venture Partner, Polaris Venture Partners
     *  Dr. Cherry A. Murray, Senior Vice President of Physical Science
        Research, Bell Labs/Lucent Technologies
     *  Nicholas Negroponte, Director, MIT Media Laboratory
     *  Dr. Judith Rodin, President, University of Pennsylvania

    About Technology Review Inc.
    Re-launched in 1998 as "MIT's Magazine of Innovation," Technology Review
is the world's oldest technology magazine. The magazine, as well as its
signature events and Internet businesses, delivers essential information on
emerging technologies on the verge of commercialization is a diversified media
enterprise that. Since its re-launch, Technology Review's paid circulation has
more than tripled, from 92,000 to 310,000 (as of January 2002). Several
hundred thousand current MIT alumni, faculty and students, senior technology
thinkers and influencers - venture capitalists, chief scientists, researchers,
senior corporate executives, investors, and innovators throughout the world --
constitute the Technology Review community.

    About Epigenomics
    Epigenomics is a transatlantic biotechnology company, with headquarters in
Berlin, Germany and its wholly owned subsidiary in Seattle, Washington, USA,
pioneering tomorrow's personalized medicines. By detecting DNA methylation
patterns, the "on" and "off" signs for genes, Epigenomics can create a
digitized readout (Digital Phenotype(R)) for each tissue. The comparison of
healthy and sick tissue enables an exact diagnosis of disease at a very early
stage and reveals new therapeutic opportunities. The combination of diagnosis
and therapy, based on this epigenetic information and our robust proprietary
technology, is leading the way to improving patients' quality of life.
Epigenomics is the world's first and only company focusing exclusively on DNA
methylation and its importance in the post-genomic age, and is supported by
the world's premier network of academic researchers and clinicians with
expertise in the field of cancer and DNA methylation. For further information,
please visit our website at http://www.epigenomics.com.

Link to this page: